



Newsletter 17 December 2018

RhoVac announces that the first patient completed the follow-up phase of the clinical phase I / II study

RhoVac AB ("RhoVac") announce today, 17th December 2018, that the first prostate cancer patient included in the clinical phase I / II study with RhoVac's drug candidate RV001 has completed it's 12-month follow-up and thus the entire clinical phase I / II- study.

Prior to the clinical phase I / II study, conducted between 2017 and 2018, 22 patients with diagnosed prostate cancer and prostatectomized. Blood samples were taken before, during and after the study to analyse the product mediated immune response to treatments. The results, reported earlier this year, showed a significant immune response in 86% of the patients. Patients have also participated in a 3-, 6-, 9- and 12-month follow-up phase of the study, to assess the duration of the immune response.

RhoVac announces that the first patient has completed his 12-month follow-up and thus also completed his participation in RhoVac's phase I / II clinical study. The samples for immunological analysis have been sent to the University of Tübingen. The interim report on the duration of the immunological responses, from all participating patients' 3- and 6-month follow-up will be published in January 2019.

The last patient is expected to complete his 12-month follow-up in March 2019. The final report on the duration of the immunological responses is expected in the second quarter of 2019.

The company's drug candidate RV001 activates T cells of the immune system to identify and eliminate cancer cells expressing the protein RhoC. As RhoC is generally overexpressed in metastatic cancer cells, RV001 can potentially be used in the treatment of several different cancer indications. It is the company's ambition that the product being developed shall be used as a preventive treatment against metastases, thus preventing, or limiting the spread and recurrence of cancer.

For more information, please contact:

Anders Ljungqvist – CEO, RhoVac AB
Phone: +45 4083 2365
E-mail: alj@rhovac.com

About RhoVac AB

RhoVac AB conducts research and development of immunotherapeutic drugs. The company's main focus is the development of a therapeutic cancer vaccine with the potential to prevent or limit metastasis in cancer. RhoVac's top-line results from the clinical phase I / II study were published in August 2018. RhoVac has its head office at Medicon Village in Lund, Sweden. The research has been conducted since 2007 at the University Hospital in Herlev, Denmark, by a world-class research team in its niche. RhoVac is listed on Spotlight Stok Market, Sweden, a Multilateral Trading Facility (MTF), since March 2016. The share is traded under the ticker RHOVAC. Read more at www.rhovac.com.